IPP Bureau
World No Tobacco Day: HCG Cancer Hospital Mumbai holds awareness campaigns
By IPP Bureau - June 01, 2026
Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26
By IPP Bureau - June 01, 2026
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
proRITHM ranked among top healthcare innovations in Andhra Pradesh
By IPP Bureau - June 01, 2026
AI-enabled wearable remote patient monitoring platform successfully completed pilot deployments in a government super-specialty hospital and emergency ambulances
Takeda promotes Garima Srivastava as VP HR, Global Head of Talent Acquisition for Commercial
By IPP Bureau - June 01, 2026
Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning
Sanofi brings AI-driven rare disease diagnostic tool AccelRare to India
By IPP Bureau - June 01, 2026
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Redcliffe Labs appoints Vijay T. S. as Chief People Officer
By IPP Bureau - June 01, 2026
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
Zydus secures FDA priority review for Saroglitazar NDA in Primary Biliary Cholangitis
By IPP Bureau - June 01, 2026
FDA sets November 27, 2026 PDUFA date as Phase 3 EPICS-III trial demonstrates significant biochemical response and favorable safety profile in PBC patients
National Policy Dialogue adopts landmark 10-point declaration for people with disabilities
By IPP Bureau - June 01, 2026
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
Samsung Bioepis launches Aflibercept biosimilar OPUVIZ across Europe
By IPP Bureau - June 01, 2026
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
Pfizer and Innovent Biologics strike $10 billion cancer drug deal
By IPP Bureau - June 01, 2026
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
FDA clears Cercare Medical’s CBCT perfusion technology for real-time stroke imaging
By IPP Bureau - June 01, 2026
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Europe Treponema pallidum tests market to grow at 3% CAGR through 2036
By IPP Bureau - June 01, 2026
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
Clariant bags FDA nod for bio-based PVC additives
By IPP Bureau - June 01, 2026
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
By IPP Bureau - May 31, 2026
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
By IPP Bureau - May 31, 2026
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
